Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boston Scientific Corporation |
---|---|
Information provided by: | Boston Scientific Corporation |
ClinicalTrials.gov Identifier: | NCT00301522 |
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
Condition | Intervention | Phase |
---|---|---|
Coronary Stenosis |
Device: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation Device: Express2 |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | TAXUS V: De Novo Lesion: A Randomized, Double-Blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions |
Enrollment: | 1108 |
Study Start Date: | February 2003 |
Estimated Study Completion Date: | April 2009 |
Primary Completion Date: | December 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Device: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation
Paclitaxel-Eluting Coronary Stent, Slow-Formulation
|
Arm 2: Active Comparator |
Device: Express2
Coronary Stent System
|
The primary endpoint is the incidence rate of TVR through 9 months post index procedure. In this protocol, TVR must be ischemia driven, based on the presence of symptoms, positive functional testing or Quantitative Coronary Angiography (QCA) severity of restenosis.
Secondary endpoints include the following:
Additional angiographic endpoints to be measured in all patients with 9 month angiographic follow-up include:
IVUS Substudy
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Gregg W. Stone, MD | Columbia University Medical Center |
Principal Investigator: | Stephen G. Ellis, MD | The Cleveland Clinic |
Responsible Party: | Boston Scientific ( Kristan Tilton ) |
Study ID Numbers: | TAXUS V De novo, S5442 |
Study First Received: | March 9, 2006 |
Last Updated: | October 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00301522 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
Coronary Artery Stenosis Drug-eluting |
stent restenosis revascularization |
Coronary Disease Heart Diseases Paclitaxel Myocardial Ischemia Vascular Diseases |
Constriction, Pathologic Ischemia Coronary Stenosis Coronary Artery Disease |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Mitosis Modulators Tubulin Modulators |
Cardiovascular Diseases Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |